Home/Filings/4/0001415889-22-012990
4//SEC Filing

Berkenblit Anna 4

Accession 0001415889-22-012990

CIK 0000855654other

Filed

Dec 26, 7:00 PM ET

Accepted

Dec 27, 5:13 PM ET

Size

8.0 KB

Accession

0001415889-22-012990

Insider Transaction Report

Form 4
Period: 2022-05-20
Berkenblit Anna
VP & Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-11-14+222,300333,450 total
    Exercise: $4.55From: 2022-11-14Exp: 2030-02-07Common Stock (222,300 underlying)
  • Award

    Stock Option (Right to Buy)

    2022-05-20+111,150111,150 total
    Exercise: $4.55From: 2022-05-20Exp: 2030-02-07Common Stock (111,150 underlying)
Footnotes (2)
  • [F1]On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
  • [F2]On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

Issuer

ImmunoGen, Inc.

CIK 0000855654

Entity typeother

Related Parties

1
  • filerCIK 0001691868

Filing Metadata

Form type
4
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 5:13 PM ET
Size
8.0 KB